Analysis-Tariffs, geopolitics drag on European IPOs, even as funds flow in


By Charlie Conchie and Emma-Victoria Farr

LONDON/FRANKFURT (Reuters) -Tariffs and Middle East turmoil are spooking European companies and the investors weighing their initial public offerings even as volatility subsides and money flows back into equity markets, advisers told Reuters.

President Donald Trump’s announcement of sweeping tariffs targeting imports from nearly all U.S. trading partners in April and his subsequent U-turn pause on the levies sent shockwaves through the global economy.

But markets, including those in Europe, have since bounced back. The VIX, Wall Street’s “fear gauge”, has fallen around 67% from a peak touched following Trump’s tariff announcement. And fund inflows into European stocks reached their second-highest level this century earlier this year.

Still, investors remain wary of new listings.

Topping their list of concerns, according to seven IPO advisers interviewed by Reuters, are the potential impact of conflicts like the Israel-Iran war and uncertainty regarding newly listed companies’ aftermarket performance.

“There’s still a bit of nervousness in the network and a hangover from issues around tariffs and the war in the Middle East,” said Scott McCubbin, head of EY’s UK and Ireland IPO practice.

Some companies, meanwhile, are unwilling to accept lower valuations than they had hoped for, the advisers said.

SHELVED LISTINGS

German medical technology firm Brainlab postponed its IPO this week, citing “geopolitical uncertainties”.

Pharmaceutical company Stada delayed its debut in March, citing market volatility, while another German firm, car parts seller Autodoc did the same last month without giving a reason. Glencore-backed metals investor Cobalt Holdings, which was planning London’s biggest IPO of 2025, meanwhile failed to secure enough investor interest, a person familiar with the matter told Reuters previously. Cobalt Holdings declined to comment.

The recent run of shelved listings is making things harder for firms attempting to reopen the IPO market, one person close to the Brainlab IPO process said.

Investors could not agree a price for the offering with Brainlab, the person and a second source said. Existing shareholders were dissatisfied with the makeup of the order book, said one of the sources, both of whom spoke on condition of anonymity because the process was private.

A spokesperson for Brainlab said interest from investors was “very strong” but the conditions were not optimal for an IPO.

While more funds have flowed into European equities this year from investors seeking to reduce their exposure to U.S. assets, that money is going into the stocks of large companies rather than IPOs, said one equity capital markets banker.

More From Author

Magic re-signing C Moritz Wagner to 1-year, $5M deal

The ‘2025 MLB All-Star Starters’ quiz

Leave a Reply

Your email address will not be published. Required fields are marked *